Stay current with the latest press releases from within the industry.
Release issued 27th January 2004
West Pharmaceutical Services, Inc. (NYSE: WST) today reported Phase I clinical trial data on its nasal fentanyl product for breakthrough pain. The data was presented at the 8th Annual Drug Delivery Partnerships conference in Beverly Hills, CA.
The objective of the study was to compare the single-dose bioavailability and pharmacokinetics of three different novel nasal fentanyl formulations incorporating the Company's proprietary delivery technology with the commercially available oral transmucosal dosage form. Fentanyl is an opioid analgesic commonly used for the treatment of breakthrough pain in cancer patients. The study involved 18 healthy male and female subjects.
The study results showed that nasal treatments appeared to be absorbed more rapidly and gave higher plasma concentration values despite a lower dose level compared to the oral transmucosal dosage form.
"We are particularly excited by the comparative rapid delivery of fentanyl to the bloodstream by our nasal formulation," said Bruce S. Morra, Ph.D., President of West's Drug Delivery Systems Division. "The product offers the potential for a quick onset of action for breakthrough pain relief. West is planning additional clinical trials, while simultaneously pursuing licensing opportunities."
If you want to find out more about the company visit West Pharmaceutical Services profile.
Clients in focus...